Home › Funds › Ally Bridge Group (NY) LLC › AVTX
Ally Bridge Group (NY) LLC position in AVTX
AVALO THERAPEUTICS INC · Health Care
Ally Bridge Group (NY) LLC reported holding 150,000 shares of AVTX (AVALO THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$2.8M, representing 2.45% of its reported portfolio and ranking #13 among its reported holdings. Ally Bridge Group (NY) LLC has disclosed AVTX holdings in 2 of the last 4 reported quarters, going back to Q3 2025.
Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR
How Ally Bridge Group (NY) LLC's AVTX position evolved
Ally Bridge Group (NY) LLC first disclosed a stake in AVTX in Q3 2025 at 178,100 shares (US$2.3M). The position peaked in Q2 2026 at 150,000 shares, worth US$2.8M. Across 2 filings, Ally Bridge Group (NY) LLC held the position steady without any share-count change. The most recent filing (Q2 2026) shows 150,000 shares valued at US$2.8M.
Quarter by quarter
| Quarter | Shares | Value | Change |
|---|---|---|---|
| Q3 2025 | 178.10K | $2.26M | New |
| Q2 2026 | 150.00K | $2.77M | New |
Dots on the line are colored by change type; missing quarters mean no position was reported.
About AVTX and 13F data
AVTX (AVALO THERAPEUTICS INC) is a Health Care company. 83 other funds we track also report a position in AVTX — the largest reported positions include Deep Track Capital, LP (US$66.7M), Caligan Partners LP (US$58.5M), TCG Crossover Management, LLC (US$55.8M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.
Other funds holding AVTX
- Deep Track Capital, LP 3.61M sh · $66.71M · Q2 2026
- Caligan Partners LP 3.16M sh · $58.47M · Q2 2026
- TCG Crossover Management, LLC 3.02M sh · $55.76M · Q2 2026
- Affinity Asset Advisors, LLC 2.90M sh · $53.59M · Q2 2026
- Farallon Capital Management 2.50M sh · $46.16M · Q2 2026
- FARALLON CAPITAL MANAGEMENT, L.L.C. 2.50M sh · $46.16M · Q2 2026
- Avoro Capital Advisors LLC 2.33M sh · $43.12M · Q2 2026
- BVF INC/IL 2.08M sh · $38.36M · Q2 2026
- Nantahala Capital Management, LLC 1.86M sh · $34.41M · Q2 2026
- Soleus Capital Management, L.P. 1.65M sh · $30.58M · Q2 2026
- BRAIDWELL LP 1.63M sh · $30.11M · Q2 2026
- Logos Global Management LP 1.15M sh · $21.25M · Q2 2026
More on Ally Bridge Group (NY) LLC
FAQ
How long has Ally Bridge Group (NY) LLC held AVTX?
Ally Bridge Group (NY) LLC has disclosed AVTX holdings in 2 of the last 4 reported quarters, going back to Q3 2025.
What is Ally Bridge Group (NY) LLC's current position in AVTX?
As of Q2 2026, Ally Bridge Group (NY) LLC holds 150.00K shares of AVTX (AVALO THERAPEUTICS INC), valued at $2.77M, representing 2.45% of its reported portfolio and ranking #13.
Has Ally Bridge Group (NY) LLC been buying or selling AVTX?
In the latest 13F filing (Q2 2026), Ally Bridge Group (NY) LLC newly opened its position in AVTX. The position peaked in Q2 2026 at 150.00K shares.
Which other funds hold AVTX?
Other major institutional holders of AVTX include Deep Track Capital, LP, Caligan Partners LP, TCG Crossover Management, LLC, among 83 funds with disclosed positions.
Where does this data come from?
All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.